Category: St. Jude MedicalSyndicate content

St. Jude Medical beats The Street, loses points anyway

April 16, 2014 by Arezu Sarvestani

St. Jude Medical meets Wall Street's expectations for its 1st quarter of 2014 with moderate sales growth across its product lines, but shares take a downward turn in morning trading.

St. Jude Medical meets The Street, loses points anyway

Minnesota medtech titan St. Jude Medical (NYSE:STJ) lost a few points on Wall Street today after posting 1st quarter earnings a penny above analysts' consensus estimate.

March 2014 Medical device recalls | Medtech regulatory news for the week of Apr. 7, 2014

April 8, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week.

Medical device recalls for March 2014

April 2, 2014 by MassDevice staff

FDA logo

March Summary
Class I recalls: 10
Class II recalls: 183

Medtech trends: The most talked about device makers in March 2014

April 2, 2014 by Arezu Sarvestani

MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.

chart

Click to enlarge.

MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.

ACC 2014 UPDATE: Reaction to Medtronic's Symplicity renal denervation data

March 31, 2014 by Brad Perriello

Medtronic's Symplicity renal denervation device for hypertension lowered blood pressure only slightly more than patients treated with drugs and a sham procedure, the company said Saturday at the American College of Cardiology's annual conference.

ACC 2014 UPDATE: Reaction to Medtronic's Symplicity renal denervation data

Medtronic (NYSE:MDT) revealed the details of a clinical trial of its Symplicity renal denervation treatment for hypertension, but said it still plans to investigate the treatment even though the study showed only meager improvements in high blood pressure compared with a sham procedure.

St. Jude's Nanostim pacemaker looks good at 3 months in feasibility study

March 25, 2014 by Brad Perriello

A small European feasibility study of the Nanostim leadless pacemaker acquired by St. Jude Medical looks good at 3 months, according to a study published in the American Heart Assn. journal Circulation.

St. Jude's Nanostim pacemaker looks good at 3 months in feasibility study

The Nanostim leadless pacemaker acquired by St. Jude Medical (NYSE:STJ) last year appeared safe and functional after 3 months, according to results of a small study published in the American Heart Assn. journal Circulation.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp